Prescribing information for LUTATHERA® (lutetium (177Lu) oxodotreotide (external link)
Prescribing information for Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) (external link)

This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.

 Radioligand therapy (RLT)

Hero banner.

Article
4 mins

The science of RLT and Novartis RLT services

Hero banner.

Article
1 min

Explore RLT Services

Article
- 08 Sep 2025
1 min
Hero banner.

Article
3 mins

RLT manufacturing and logistics

Article
- 08 Sep 2025
3 mins
Hero banner.

Article
1 min

Find an RLT treatment centre

Article
- 10 Jul 2024
1 min

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.